Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NX-501
- Development stage
- Preclinical
- Lead developer
- Guangzhou Nanxin Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NX-501 is a non-steroidal, highly selective mineralocorticoid receptor (MR) antagonist being developed by Guangzhou Nanxin Pharmaceutical (Nucien). Currently in the preclinical stage, it is being investigated for the treatment of diabetic nephropathy, hypertension, and heart failure. As a non-steroidal small molecule, NX-501 is designed to bind to the mineralocorticoid receptor with high affinity and selectivity, aiming to provide potent anti-inflammatory and anti-fibrotic effects while minimizing the risk of hyperkalemia and off-target effects on other steroid receptors (such as the androgen or progesterone receptors) that are commonly associated with traditional steroidal MR antagonists like spironolactone and eplerenone.
- Other names
- MR拮抗剂Non-steroidal highly selective MR antagonist
Beyond the preview
Go deeper on NX-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NX-501.